NATCO Pharma Limited - Legal update regarding Risdiplam

NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today updates on the legal proceedings on Risdiplam in India.

With reference to earlier update on 9th October 2025, the Commercial Appellate Division of the Hon'ble Delhi High Court, in the Risdiplam suit, was challenged by the Swiss Pharmaceutical Company F. Hoffmann-La Roche AG before the Supreme Court of India. The Apex Court took note of the concurrent findings of the Ld. Single Judge as well as the Division Bench of the Delhi High Court in denying injunctions against NATCO Pharma Limited. Having the benefit of the two successive orders, the Supreme Court was not convinced about the maintainability of the challenge by Roche and, therefore, dismissed the petition. This marks the final challenge Roche could have posed at the interim stage in the suit, which shall now proceed for trial in accordance with the law. Senior Advocate J. Sai Deepak appeared for NATCO before the Learned Single Judge and Division Bench of the Hon'ble Delhi High Court and was assisted by the counsels on record S. Majumdar and Co. In the Supreme Court, NATCO was represented by Senior Advocates Kapil Sibal, Gopal Subramanium and J. Sai Deepak and were instructed by S. Majumdar and Co and KMNP Law.

Spinal Muscular Atrophy (SMA) is one of the leading causes of death in infants related to the degeneration of neurons. Currently, there are no curative treatment options for SMA, and most of the available options are not financially feasible for Indian patients. This ruling would bring some hope to the countless lives that have been debilitated by an ailment like SMA.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 826.20 as compared to the previous close of Rs. 821.75. The total number of shares traded during the day was 49181 in over 2492 trades.

The stock hit an intraday high of Rs. 847.25 and intraday low of 815.70. The net turnover during the day was Rs. 40893581.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 Pharmaceuticals LegalUpdate Risdiplam